Australia
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address therapeut...
2026-06-25 22:51
1968
Marketplacer Joins Snowflake's MCD Program to Accelerate AI-Powered Autonomous Commerce
Expanded collaboration enables enterprise retailers, brands, and operators to unlock real-time marketplace intelligence and automate supply-side operations through the Snowflake AI Data Cloud MELBOURNE, Australia, June 23, 2026 /PRNewswire/ -- Marketplacer, the global marketplace platform enabli...
2026-06-23 14:00
1938
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 19:00
2206
BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS
SYDNEY, June 15, 2026 /PRNewswire/ -- Bifox Limited ("Bifox") is pleased to advise it has entered into two agreements with Fossal S.A.A ("Fossal"), to purchase all of the shares of Fosfatos del Pacífico S.A. ("Fospac"). Under the agreements, Bifox has paid US$10 million cash for 16.667% of the ou...
2026-06-16 08:52
3211
![BIFOX ENTERS INTO AGREEMENTS TO ACQUIRE THE 550 MILLION TONNE[1] BAYOVAR 9 PHOSPHATE ROCK PROJECT IN PERU POSITIONING BIFOX TO BECOME ONE OF THE LEADING GLOBAL PHOSPHATE ROCK SUPPLIERS](https://mma.prnasia.com/media2/2996544/image1.jpg?p=medium600)
Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The ...
2026-06-11 16:22
4333
Infomedia Announces Acquisition of Veact in Europe, Expanding Global Automotive Aftersales Ecosystem
SYDNEY and MUNICH, June 9, 2026 /PRNewswire/ -- Infomedia, a global leader in automotive aftersales technology, has completed the acquisition of Veact GmbH, a leading European provider of data activation, predictive service marketing, and aftersales customer management solutions in the automotive...
2026-06-09 16:00
4034
Fibocom Showcases Smart Connectivity Solutions for AIoT at ElectroneX 2026
SYDNEY, June 3, 2026 /PRNewswire/ -- Fibocom showcased its latest AIoT innovations at ElectroneX 2026 in Australia from June 3–4 at booth D36 under the theme "Intelligent Connectivity for a Smarter World." Targeting the ANZ market, Fibocom presented wireless connectivity solutions for smart payme...
2026-06-03 16:52
4672
HEALEY ALS Platform Trial Regimen I expands to 240 participants
Highlights: * Neurizon announces an expansion to the size of Regimen I intended to support a larger and more informative dataset, with accelerated time to topline readout and no change in funding requirements * Increase in sample size driven by enrolment rate exceeding original expectations ...
2026-05-27 22:41
6152
World's smallest deployable operational optical ground station proves capability in successful trials
* Data transferred securely and rapidly between space and ground * Compatible with U.S. Space Development Agency standard * UK Space Minister Liz Lloyd welcomed the news * Units for purchase and service contracts available OXFORD, England, May 27, 2026 /PRNewswire/ -- Archangel Lightworks, ...
2026-05-27 15:00
3630
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued
Encouraging Safety and Tolerability Data
SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics
2026-05-26 19:30
4118
Decision Governance to Enhance Accountability and Transparency of Decisions in Enterprises
The decision governance gap was always there. AI agents just made it impossible to ignore. MELBOURNE, Australia, May 19, 2026 /PRNewswire/ -- FlexRule makes the case that accountability, explainability, and decision quality are not AI problems. They are governance problems that enterprises have ...
2026-05-19 13:52
5131
DAVE & BUSTER'S OPENS IN PERTH AS BRAND CONTINUES GLOBAL EXPANSION
Dave & Buster's makes its Australia debut, expanding its Asia-Pacific footprint Key Highlights * First Dave & Buster's location in Australia opens in Perth. * New venue combines dining, sports viewing and competitive social gaming under one roof. * The opening advances Dave & Buster's conti...
2026-05-19 04:01
4556
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...
2026-05-15 22:25
9053
Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial
Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...
2026-05-15 19:06
4704
EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...
2026-05-14 13:03
2959
Razor Labs Wins Gold Globee® Award for AI Innovation in Mining Fleet Reliability
DataMind AI™ for mobile fleet recognized in the "Anomaly Detection & Pattern Recognition Platform" category SYDNEY, May 12, 2026 /PRNewswire/ -- Razor Labs (TASE: RZR), a global leader in AI-powered predictive maintenance solutions for the mining industry, today announced that it has been named ...
2026-05-12 06:00
2860
(E,E)-bisantrene Discovered to Function via Silencing of c-MYC Expression
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity SYDNEY, May 6, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical c...
2026-05-06 19:00
4044
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...
2026-05-06 05:01
3394
MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
* Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in Australia for adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a).1,2 * De...
2026-04-23 15:00
3748
Proudly Human announces Manager Tools as the world's first officially certified podcast as the world struggles to distinguish between AI-generated and human-created content
SYDNEY, April 22, 2026 /PRNewswire/ -- Proudly Human has announced its
certification of all content from global company Manager Tools
2026-04-22 20:32
2925
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
5686
E Fund (HK) HKEX Tech 100 Index ETF (3456) Lists Today
2026-06-26 17:19
5160
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5108
